

## Technology Advisory Committee A Interests Register

**Topic: Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma cancer [ID2712]**

**Publication Date: 8/2/2023**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Elizabeth Smyth	Clinical expert	Direct non-financial	Dr Smyth is co-chair of the EORTC (European Organisation for Research and Treatment of Cancer) Gastric Cancer Taskforce; member of the ESMO Guidelines Committee and Senior author of the Gastric and Oesophageal guidelines.		28/01/22	N/A	It was agreed that this declaration would not prevent them from providing expert advice in this discussion.
Dr Wasat Mansoor	Clinical expert	Direct financial	Dr Mansoor has received payments for advisory boards with BMS and MSD.		18/03/22	N/A	It was agreed that this declaration would not prevent them from providing expert advice in this discussion.
Dr Radha Todd	TAC Committee Member	Direct financial interest	Dr Todd been a member of a Pfizer advisory board between September and November 2021		28/08/22	N/A	It was agreed that this declaration would not prevent them from participating in this discussion.

### GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.